PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of bmccancBioMed Centralsearchsubmit a manuscriptregisterthis articleBMC Cancer
 
BMC Cancer. 2012; 12: 337.
Published online 2012 August 2. doi:  10.1186/1471-2407-12-337
PMCID: PMC3487844
C-reactive protein in patients with advanced metastatic renal cell carcinoma: Usefulness in identifying patients most likely to benefit from initial nephrectomy
Hiroki Ito,corresponding author1 Koichi Shioi,2 Takayuki Murakami,1 Akitoshi Takizawa,2 Futoshi Sano,1 Takashi Kawahara,1 Nobuhiko Mizuno,1 Kazuhide Makiyama,1 Noboru Nakaigawa,1 Takeshi Kishida,2 Takeshi Miura,2 Yoshinobu Kubota,1 and Masahiro Yao1
1Department of Urology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa 236-0004, Japan
2Department of Urology, Kanagawa Cancer Center, Yokohama, Japan
corresponding authorCorresponding author.
Hiroki Ito: pug_daikichi/at/yahoo.co.jp; Koichi Shioi: kshioi501/at/hotmail.com; Takayuki Murakami: t-murazo/at/wb3.so-net.ne.jp; Akitoshi Takizawa: akitoshignt/at/yahoo.co.jp; Futoshi Sano: fsano/at/yokohama-cu.ac.jp; Takashi Kawahara: takashi_tk2001/at/yahoo.co.jp; Nobuhiko Mizuno: mizuno.nobuhiko/at/gmail.com; Kazuhide Makiyama: makiya/at/yokohama-cu.ac.jp; Noboru Nakaigawa: nakaigan/at/med.yokohama-cu.ac.jp; Takeshi Kishida: thwmtkishida/at/yahoo.co.jp; Takeshi Miura: tamiura/at/kcch.jp; Yoshinobu Kubota: urol_sec/at/yokohama-cu.ac.jp; Masahiro Yao: masayao/at/med.yokohama-cu.ac.jp
Received April 3, 2012; Accepted July 24, 2012.
Abstract
Objective
C-reactive protein (CRP) is considered a useful serum marker for patients with RCC. However, its clinical utility in advanced metastatic renal cell carcinoma (AM-RCC), particularly in deciding whether to perform nephrectomy at the onset, is not well studied.
Patients and methods
We retrospectively evaluated 181 patients with AM-RCC, including 18 patients underwent potentially curative surgery, 111 underwent cytoreductive nephrectomy, and 52 received medical treatment only. CRP cutoff points were determined by receiver operating characteristic (ROC) curve analysis. Kaplan-Meier and Cox regression analyses were used for survival tests.
Results
ROC analysis suggested that grouping patients according to 3 CRP ranges was a rational model. Patients with highly elevated CRP (≥67.0 mg/L) presented remarkably poor prognosis despite treatment (nephrectomy or medical treatment only). Cox regression models demonstrated that risk factors of overall survival for patients who underwent nephrectomy were the CRP ranges defined in this study (≤18.0 mg/L, >18.0 and <67.0 mg/L, and ≥67.0 mg/L), ECOG PS (0, 1, and ≥2), and number of metastatic organ sites (0–1 and ≥2). The retrospective design is a limitation of this study.
Conclusion
Our study demonstrated that the serum CRP level is a statistically significant prognostic parameter for patients with AM-RCC. The data also indicated that pretreatment serum CRP level provides useful prognostic information that helps in deciding whether to perform initial nephrectomy for patients with AM-RCC.
Keywords: C-reactive protein, Rena cell carcinoma, Prognosis
Articles from BMC Cancer are provided here courtesy of
BioMed Central